NCT04222062View on ClinicalTrials.gov

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Brain Tumor - Metastatic
Interventions
DRUG

Carmustine 7.7Mg Wafer

GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.

Trial Locations (2)

48202

NOT_YET_RECRUITING

Henry Ford, Detroit

68198

RECRUITING

University of Nebraska Medical Center, Omaha

Sponsors
All Listed Sponsors
collaborator

Arbor Pharmaceuticals, Inc.

INDUSTRY

lead

University of Nebraska

OTHER

NCT04222062 - A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease | Biotech Hunter | Biotech Hunter